⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL27374322 | 0.60 | — | — | |
| Trimethylammonium SCHEMBL28007346 | 0.60 | — | — | |
| SCHEMBL13278651 | 0.59 | — | — | |
| SCHEMBL13278640 | 0.59 | — | — | |
| SCHEMBL19288029 | 0.59 | — | — | |
| SCHEMBL181649 | 0.59 | — | — | |
| SCHEMBL64854 | 0.56 | — | — | |
| SCHEMBL18455720 | 0.56 | — | — | |
| SCHEMBL13428497 | 0.56 | — | — | |
| SCHEMBL770520 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571459-B2 | Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents | ONCXERNA THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20180289771-A1 | METHODS FOR TREATING CANCER USING PS-TARGETING ANTIBODIES WITH IMMUNO-ONCOLOGY AGENTS | ONCXERNA THERAPEUTICS, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20160311886-A1 | Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
| EP-2424351-B1 | ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-10-21 | — | — | EP | disclosed |
| US-9000036-B2 | Compositions and methods for targeting of treating neoplasms | Yu, Baofa (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2324006-B1 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2014-08-13 | — | — | EP | disclosed |
| US-20140205544-A1 | Cancer Treatment Comprising Therapeutics That Bind To Phosphatidylserine | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-24 | — | — | US | disclosed |
| US-8653034-B2 | Compositions and methods comprising phosphatidylethanolamine-binding peptide derivatives | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140037695-A1 | COMPOSITIONS AND METHODS FOR TARGETING OF TREATING NEOPLASMS | YU, BAOFA | 2014-02-06 | — | — | US | disclosed |
| US-20130243756-A1 | Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-19 | — | — | US | disclosed |
| US-7378386-B2 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070190550-A1 | Novel compositions and methods for the identification, assessment, prevention, and therapy of human cancers | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7247303-B2 | Selected antibody CDRs for binding to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050129696-A1 | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM | 2005-06-16 | — | — | US | disclosed |
| US-20050031620-A1 | Combined cancer treatment methods using selected antibodies to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-02-10 | — | — | US | disclosed |
| US-20050025761-A1 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-02-03 | — | — | US | disclosed |
| US-20050002941-A1 | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-01-06 | — | — | US | disclosed |
| US-5116954-A | Antitumor agents | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1992-05-26 | — | — | US | disclosed |
| EP-0447331-A2 | An optical article exhibiting a high level of second order polarization susceptibility | EASTMAN KODAK COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
| US-5008043-A | Transmission of electromagnetic radiation; containing a medium characterized in that the sulfonyl electron acceptor moiety has at least two halogen substituents on its alpha carbon atom | EASTMAN KODAK COMPANY (US) | 1991-04-16 | — | — | US | disclosed |